Compare Biogen Inc (BIIB) vs Centrus Energy Corp (LEU) Price & Performance

Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.

The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.

Centrus Energy (LEU) trades at $156.05, down 8.77% over 24 hours amid bearish technical signals. The stock shows mixed fundamentals with a high P/E of 57.96 but strong net income margin of 13.4%. Recent positive developments include a $1 billion DOE contract expansion and inclusion in the S&P SmallCap 600 index, though earnings have been inconsistent with two misses and one beat in recent quarters.

The outlook remains cautiously optimistic given strong government contracts and nuclear industry tailwinds, but elevated valuation and recent earnings volatility present risks. Analyst consensus price target of $223.14 suggests 43% upside potential, though technical indicators signal near-term bearish pressure with support at $151.